BL-B01D1 binds EGFR/HER3 on tumor cells, is internalized, and releases a camptothecin topoisomerase I inhibitor that induces DNA damage; Topoisomerase I is the payload’s enzymatic target, not the antibody-recognized cytotoxic target.